$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010107 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.522M	$14.24M	$14.24M
YoY Change	-4.73%	470.66%	42.74%
Cost Of Revenue	$1.335M	$5.833M	$5.833M
YoY Change	-15.83%	539.58%	11.23%
Gross Profit	$2.187M	$8.405M	$8.405M
YoY Change	3.6%	430.95%	77.66%
Gross Profit Margin	62.1%	59.03%	59.03%
Selling, General & Admin	$2.142M	$8.911M	$8.911M
YoY Change	0.85%	522.28%	17.36%
% of Gross Profit	97.94%	106.02%	106.02%
Research & Development	$212.0K	$873.0K	$873.0K
YoY Change	-11.3%	-14650.0%	-30.44%
% of Gross Profit	9.69%	10.39%	10.39%
Depreciation & Amortization	$11.00K	$51.00K	$214.0K
YoY Change	22.22%	-5.56%	-1.83%
% of Gross Profit	0.5%	0.61%	2.55%
Operating Expenses	$2.387M	$9.998M	$9.998M
YoY Change	-1.24%	575.54%	10.28%
Operating Profit	-$200.0K	-$1.593M	-$1.593M
YoY Change	-34.64%	-1646.6%	-63.25%
Interest Expense	$1.000K	$62.00K	$62.00K
YoY Change	0.0%	1450.0%	-1133.33%
% of Operating Profit
Other Income/Expense, Net	$31.00K	-$44.00K	-$44.00K
YoY Change		46.67%	-168.75%
Pretax Income	-$169.0K	-$1.575M	-$1.575M
YoY Change	-44.77%	-2145.45%	-63.18%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$169.0K	-$1.575M	-$1.575M
YoY Change	-44.77%	71.57%	-78.66%
Net Earnings / Revenue	-4.8%	-11.06%	-11.06%
Basic Earnings Per Share	-$0.02		-$0.15
Diluted Earnings Per Share	-$0.02	-$0.15	-$0.15
COMMON SHARES
Basic Shares Outstanding	10.54M shares	10.48M shares	10.39M shares
Diluted Shares Outstanding	10.50M shares		10.39M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.633M	$4.307M	$4.307M
YoY Change	-5.29%	18.52%	18.52%
Cash & Equivalents	$3.633M	$4.307M
Short-Term Investments
Other Short-Term Assets	$200.0K	$132.0K	$132.0K
YoY Change	12.99%	-29.79%	-29.79%
Inventory	$2.779M	$2.470M	$2.470M
Prepaid Expenses
Receivables	$1.518M	$1.496M	$1.496M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.130M	$8.405M	$8.405M
YoY Change	-2.33%	1.74%	1.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$142.0K	$1.959M	$1.959M
YoY Change	32.71%	78.09%	78.09%
Goodwill	$800.0K	$800.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$75.00K	$86.00K	$86.00K
YoY Change	25.0%	59.26%	59.26%
Total Long-Term Assets	$3.286M	$3.456M	$3.456M
YoY Change	26.24%	26.22%	26.22%
TOTAL ASSETS
Total Short-Term Assets	$8.130M	$8.405M	$8.405M
Total Long-Term Assets	$3.286M	$3.456M	$3.456M
Total Assets	$11.42M	$11.86M	$11.86M
YoY Change	4.48%	7.84%	7.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.114M	$873.0K	$873.0K
YoY Change	54.94%	17.97%	17.97%
Accrued Expenses	$413.0K	$1.240M	$1.240M
YoY Change	7.83%	106.32%	106.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000K	$0.00	$0.00
YoY Change	-71.43%	-100.0%	-100.0%
Total Short-Term Liabilities	$1.929M	$2.113M	$2.113M
YoY Change	36.33%	49.65%	49.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$1.307M	$1.390M	$1.390M
YoY Change	112.18%	97.16%	97.16%
Total Long-Term Liabilities	$1.307M	$1.390M	$1.390M
YoY Change	111.49%	96.88%	96.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.929M	$2.113M	$2.113M
Total Long-Term Liabilities	$1.307M	$1.390M	$1.390M
Total Liabilities	$3.236M	$3.503M	$3.503M
YoY Change	59.17%	-35.21%	-35.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$144.6M	-$144.4M
YoY Change	1.05%	1.12%
Common Stock	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.180M	$8.358M	$8.358M
YoY Change
Total Liabilities & Shareholders Equity	$11.42M	$11.86M	$11.86M
YoY Change	4.48%	7.84%	7.84%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$169.0K	-$1.575M	-$1.575M
YoY Change	-44.77%	71.57%	-78.66%
Depreciation, Depletion And Amortization	$11.00K	$51.00K	$214.0K
YoY Change	22.22%	-5.56%	-1.83%
Cash From Operating Activities	-$672.0K	-$238.0K	$827.0K
YoY Change	-343.48%	22.05%	-125.57%
INVESTING ACTIVITIES
Capital Expenditures		$75.00K	$75.00K
YoY Change			-45.26%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00	-$75.00K	-$75.00K
YoY Change			-45.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.000K	-3.000K	-79.00K
YoY Change	-97.3%	-97.3%	-332.35%
NET CHANGE
Cash From Operating Activities	-$672.0K	-238.0K	827.0K
Cash From Investing Activities	0.000	-75.00K	-75.00K
Cash From Financing Activities	-$2.000K	-3.000K	-79.00K
Net Change In Cash	-$674.0K	-316.0K	673.0K
YoY Change	-433.66%	3.27%	-120.16%
FREE CASH FLOW
Cash From Operating Activities	-$672.0K	-$238.0K	$827.0K
Capital Expenditures		$75.00K	$75.00K
Free Cash Flow		-$313.0K	$752.0K
YoY Change		60.51%	-122.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent		usd
CY2023Q4	NEPH	Equipment Financing Debt Non Current EquipmentFinancingDebtNonCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
CY2023	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare
CY2023	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance		usd
CY2023	NEPH	Cashless Exercise Of Stock Options Value CashlessExerciseOfStockOptionsValue		usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2023	NEPH	Payments To Employee Taxes On Restricted Stock PaymentsToEmployeeTaxesOnRestrictedStock		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization		usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://nephros.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrent
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive		usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential		pure
CY2022	NEPH	Effective Income Tax Rate Reconciliation Net Operating Loss Tax Credit Paycheck Protection Loan EffectiveIncomeTaxRateReconciliationNetOperatingLossTaxCreditPaycheckProtectionLoan		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	NEPH	Deferred Tax Assets Fixed Intangible Asset Basis Difference DeferredTaxAssetsFixedIntangibleAssetBasisDifference		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-32288
CY2023	dei	Entity Registrant Name EntityRegistrantName	NEPHROS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3971809
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	380 Lackawanna Place
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South Orange
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07079
CY2023	dei	City Area Code CityAreaCode	(201)
CY2023	dei	Local Phone Number LocalPhoneNumber	343-5202
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	NEPH
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10420918	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10543675	shares
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Tewksbury,
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4307000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3634000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1496000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1286000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2470000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3153000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	132000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	188000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8405000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8261000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	152000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116000	usd
CY2023Q4	NEPH	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	1807000	usd
CY2022Q4	NEPH	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	984000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	381000	usd
CY2022	us-gaap	Interest Expense InterestExpense	20000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	64000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	14000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	423000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	759000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	759000	usd
CY2023Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	271000	usd
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	402000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	86000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54000	usd
CY2023Q4	us-gaap	Assets Assets	11861000	usd
CY2022Q4	us-gaap	Assets Assets	10999000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	71000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	873000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	740000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	794000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	285000	usd
CY2023Q4	NEPH	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	446000	usd
CY2022Q4	NEPH	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	316000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2113000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1412000	usd
CY2022Q4	NEPH	Equipment Financing Debt Non Current EquipmentFinancingDebtNonCurrent	1000	usd
CY2023Q4	NEPH	Operating And Finance Lease Liabilities Non Current OperatingAndFinanceLeaseLiabilitiesNonCurrent	1390000	usd
CY2022Q4	NEPH	Operating And Finance Lease Liabilities Non Current OperatingAndFinanceLeaseLiabilitiesNonCurrent	705000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3503000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2118000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10543675	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10543675	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10297429	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10297429	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	152754000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148413000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144406000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142831000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8358000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5592000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	3289000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8358000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8881000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11861000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10999000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14238000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9975000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5833000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5244000	usd
CY2023	us-gaap	Gross Profit GrossProfit	8405000	usd
CY2022	us-gaap	Gross Profit GrossProfit	4731000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	873000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1255000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	58000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	214000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	218000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8911000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7593000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9998000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9066000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1593000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4335000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1575000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4277000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2829000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-1575000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7106000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	276000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1575000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7382000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.15
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.15
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.42
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.42
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.28
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.28
CY2023	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.15
CY2023	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.15
CY2022	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Basic Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerBasicShare	-0.70
CY2022	NEPH	Income Loss From Continuing And Discontinued Operation Net Of Tax Per Diluted Share IncomeLossFromContinuingAndDiscontinuedOperationNetOfTaxPerDilutedShare	-0.70
CY2022	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Basic Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerBasicShare	-0.03
CY2022	NEPH	Income Loss From Continuing Operations Attributable To Noncontrolling Interest Per Diluted Share IncomeLossFromContinuingOperationsAttributableToNoncontrollingInterestPerDilutedShare	-0.03
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10386018	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10386018	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10297134	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10297134	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-1575000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7106000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1575000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7120000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	276000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1575000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7396000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14749000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7106000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	188000	usd
CY2022	NEPH	Elimination Of Cumulative Translation Adjustment Upon Closing Of Wholly Owned Foreign Subsidiary EliminationOfCumulativeTranslationAdjustmentUponClosingOfWhollyOwnedForeignSubsidiary	-64000	usd
CY2022	NEPH	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	163000	usd
CY2022	NEPH	Stock Issued During Period Value Restricted Shares Withheld For Employee Taxes StockIssuedDuringPeriodValueRestrictedSharesWithheldForEmployeeTaxes	-31000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	982000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8881000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-1575000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1052000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8358000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-1575000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7106000	usd
CY2023	us-gaap	Depreciation Depreciation	39000	usd
CY2022	us-gaap	Depreciation Depreciation	93000	usd
CY2023	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	175000	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	258000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1052000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	982000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	295000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	773000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1395000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	60000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	221000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-357000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-387000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-765000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-26000	usd
CY2023	NEPH	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	342000	usd
CY2022	NEPH	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-353000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	31000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-29000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	133000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-593000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	506000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-150000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	342000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-355000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	827000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3234000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-137000	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	188000	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	71000	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	271000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12000	usd
CY2023	NEPH	Principal Payments On Equipment Financing PrincipalPaymentsOnEquipmentFinancing	1000	usd
CY2022	NEPH	Principal Payments On Equipment Financing PrincipalPaymentsOnEquipmentFinancing	3000	usd
CY2022	NEPH	Payments To Employee Taxes On Restricted Stock PaymentsToEmployeeTaxesOnRestrictedStock	31000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	163000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-79000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	673000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3339000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3634000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6973000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4307000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3634000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	19000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1164000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	743000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zRnuuPbnH7o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_823_zhLttNwiE3sc">Organization and Nature of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets. The water filtration business is a reportable segment, referred to as the Water Filtration segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 4, 2022, the Company entered into a definitive asset purchase agreement with a third party for the sale of substantially all of the Company’s Pathogen Detection Systems (“PDS”) business, which had been previously reported as a separate reportable operating segment. As a result of the sale of the PDS business, we completely exited the PDS business. As a result, we determined that our PDS business had met the criteria for discontinued operations as of September 30, 2022. We no longer separately report the PDS business as a separate reportable segment in our financial statements including in this Annual Report for any of the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2018, the Company formed a subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. After SRP’s formation, the Company assigned to SRP all of the Company’s rights to three patents relating to the Company’s hemodiafiltration technology, which were carried at zero book value. On March 9, 2023, the SRP Stockholders approved a plan of dissolution to wind down SRP’s operations, liquidate SRP’s remaining assets and dissolve SRP. Pursuant to such plan, SRP filed a certificate of dissolution with the State of Delaware on April 13, 2023. As a result of the SRP Stockholders’ approval of the plan of dissolution and provisions therein and after satisfying all of SRP’s liabilities, there are no assets available for distribution to the holders of any of SRP’s capital stock, including its Series A Preferred Stock. As such, the value recorded to non-controlling interest was written to zero and the impact reclassified to the Company’s additional paid-in capital as the Company retained control of SRP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary U.S. facility is located at 380 Lackawanna Place, South Orange, New Jersey 07079. This location along with our Whippany, NJ facility, houses the Company’s corporate headquarters, research, manufacturing, and distribution facilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zWgIjpgluJld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zjXJzVZ26Z64">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, the assessment of the ability to continue as a going concern and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zjDXYDa3rqRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><span id="xdx_86F_zx9oIXI2r6v6">Reclassifications</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Certain reclassifications were made to the prior year’s amounts to conform to the 2023 presentation. On the Consolidated Statements of Cash Flows, Inventory impairments and writeoffs reported as $<span id="xdx_907_eus-gaap--InventoryWriteDown_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhEKpgsrM8c1" title="Inventory impairments and writeoffs">623,000</span> for the year ended December 31, 2022, was increased to $<span id="xdx_908_eus-gaap--InventoryWriteDown_c20220101__20221231_zB0GxawnDb01" title="Inventory impairments and writeoffs">773,000</span>, and Inventory reported as $<span id="xdx_90F_eus-gaap--IncreaseDecreaseInInventories_iN_di_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z1FcBo9nZMJk" title="Inventory">915,000</span> for the year ended December 31, 2022 was decreased to $<span id="xdx_905_eus-gaap--IncreaseDecreaseInInventories_iN_di_c20220101__20221231_zWs9Zv80AFzh" title="Inventory">765,000</span>, to accurately reflect the non-cash portion of the change in inventories for the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	773000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-765000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-144400000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	800000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zZlgJlnsUqu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zOq75VLKZek4">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	44000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	64000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	110000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-259000	usd
CY2022	NEPH	Disposal Group Including Discontinued Operation Research And Development Expenses DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses	637000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	535000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1175000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-1434000	usd
CY2022	NEPH	Disposal Group Including Discontinued Operation Impairment Of Assets Held For Sale DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssetsHeldForSale	-1395000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2829000	usd
CY2022Q4	NEPH	Disposal Group Including Discontinued Operation Impairment Of Assets Held For Sale DisposalGroupIncludingDiscontinuedOperationImpairmentOfAssetsHeldForSale	-1395000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	0	usd
CY2022	NEPH	Depreciation Discontinued Operations DepreciationDiscontinuedOperations	42000	usd
CY2022	NEPH	Amortization Discontinued Operations AmortizationDiscontinuedOperations	82000	usd
CY2022	NEPH	Stock Compensation Discontinued Operations StockCompensationDiscontinuedOperations	38000	usd
CY2022	NEPH	Impairment Of Assets Held For Sale Discontinued Operations ImpairmentOfAssetsHeldForSaleDiscontinuedOperations	1395000	usd
CY2022	NEPH	Operating Lease Right Of Use Assets Discontinued Operations OperatingLeaseRightOfUseAssetsDiscontinuedOperations	33000	usd
CY2022	NEPH	Purchase Of Property And Equipment Discontinued Operations PurchaseOfPropertyAndEquipmentDiscontinuedOperations	-34000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	49000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2144000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2709000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	326000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	422000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	22000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2470000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3153000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1114000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1039000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	962000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	923000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	152000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	116000	usd
CY2023	us-gaap	Depreciation Depreciation	39000	usd
CY2022	us-gaap	Depreciation Depreciation	93000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	3000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	22000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-209000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	381000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	590000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-167000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	423000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	32000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	32000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	32000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	32000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	32000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1000000.0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	800000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2300000	usd
CY2023Q4	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	EURIBOR 360-day rate plus 500 basis points calculated on the principal amount of any outstanding invoices that are overdue by more than 15 days beyond the original payment terms
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	334000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	351000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	7000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2023	NEPH	Finance Lease Cost FinanceLeaseCost	9000	usd
CY2022	NEPH	Finance Lease Cost FinanceLeaseCost	14000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	44000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	53000	usd
CY2023	us-gaap	Lease Cost LeaseCost	387000	usd
CY2022	us-gaap	Lease Cost LeaseCost	418000	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	408000	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	365000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1803000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	972000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	12000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	442000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	309000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1390000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	700000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1832000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1009000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	12000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	562000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	4000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	435000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	450000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	450000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	251000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2148000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	316000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1832000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	537000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	76000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	126000	usd
CY2023Q4	NEPH	Accrued Legal AccruedLegal	10000	usd
CY2022Q4	NEPH	Accrued Legal AccruedLegal	4000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	117000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	36000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	22000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	7000	usd
CY2023Q4	NEPH	Accrued Franchise Tax AccruedFranchiseTax	14000	usd
CY2022Q4	NEPH	Accrued Franchise Tax AccruedFranchiseTax	10000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	26000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	794000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	285000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1222	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0479	pure
CY2023	NEPH	Effective Income Tax Rate Reconciliation Net Operating Loss Tax Credit Expired EffectiveIncomeTaxRateReconciliationNetOperatingLossTaxCreditExpired	-1.1556	pure
CY2022	NEPH	Effective Income Tax Rate Reconciliation Net Operating Loss Tax Credit Expired EffectiveIncomeTaxRateReconciliationNetOperatingLossTaxCreditExpired	-0.1278	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0454	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0243	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0062	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0915	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0012	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0344	pure
CY2023	NEPH	Effective Income Tax Rate Reconciliation Net Operating Loss Tax Credit Paycheck Protection Loan EffectiveIncomeTaxRateReconciliationNetOperatingLossTaxCreditPaycheckProtectionLoan	0.1914	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.6762	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2378	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17672000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1087000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1401000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	613000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	543000	usd
CY2023Q4	NEPH	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	449000	usd
CY2022Q4	NEPH	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	243000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	2072000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	1946000	usd
CY2022Q4	NEPH	Deferred Tax Assets Fixed Intangible Asset Basis Difference DeferredTaxAssetsFixedIntangibleAssetBasisDifference	328000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	713000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	243000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21634000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22376000	usd
CY2023Q4	NEPH	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	442000	usd
CY2022Q4	NEPH	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	234000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets	116000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	558000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	234000	usd
CY2023Q4	NEPH	Deferred Tax Assets Liabilities Net Before Valuation Allowances DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances	21076000	usd
CY2022Q4	NEPH	Deferred Tax Assets Liabilities Net Before Valuation Allowances DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances	22142000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21076000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22142000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	122524	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000.0	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1426510	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	279115	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.91
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	340260	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.88
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1365365	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	583089	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.47
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	102722	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.87
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56526	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.47
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1789206	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.07
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56526	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	16576	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	968441000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.55
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1342342000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.26
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1171824000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.25
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1753398000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.12
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.99
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.25
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	58000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	600000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M19D
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023	dei	Auditor Firm AuditorFirmId	23

Files In Submission

Name	View Source	Status
0001493152-24-010107-index-headers.html	Edgar Link	pending
0001493152-24-010107-index.html	Edgar Link	pending
0001493152-24-010107.txt	Edgar Link	pending
0001493152-24-010107-xbrl.zip	Edgar Link	pending
ex10-31.htm	Edgar Link	pending
ex10-31_001.jpg	Edgar Link	pending
ex10-31_002.jpg	Edgar Link	pending
ex10-31_003.jpg	Edgar Link	pending
ex10-31_004.jpg	Edgar Link	pending
ex10-32.htm	Edgar Link	pending
ex10-34.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
neph-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
neph-20231231_cal.xml	Edgar Link	unprocessable
neph-20231231_lab.xml	Edgar Link	unprocessable
neph-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
neph-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2024 Q1 Form 10-K Financial Statement

#000149315224010107 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2024 Q1 Form 10-K Financial Statement

#000149315224010107 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph